February 17, 2004Stroke
Serial Urinary 11-Dehydrothromboxane B2, Aspirin Dose, and Vascular Events in Blacks After Recent Cerebral Infarction
Why the study?
Does aspirin dose affect urinary 11-DTB2 levels and vascular events in Black patients after recent cerebral infarction?
Population
83 Black subjects 7 to 90 days after noncardioembolic cerebral infarction
Comparison
Aspirin or ticlopidine 500 mg/d vs Different doses of aspirin or ticlopidine
Design
Cohort, 52 subjects were randomized to blinded treatment with aspirin 650 mg/d…
Follow-up
2 years
Authors
Discussion
Loading...
Member takes
Implication
11-DTB2 fluctuations should not guide aspirin dosing; leaves open its value as a vascular biomarker in Black post-stroke patients.
Structured PICO
Does aspirin dose affect urinary 11-DTB2 levels and vascular events in Black patients after recent cerebral infarction?
P
Population
83 Black subjects 7 to 90 days after noncardioembolic cerebral infarction
I
Intervention
Aspirin (various doses including 650 mg/d, 1300 mg/d, 325 mg/d, 81 mg/d) or ticlopidine 500 mg/d
C
Comparator
Different doses of aspirin or ticlopidine
O
Outcome
Reproducibility of urinary 11-dehydrothromboxane B2 (11-DTB2) over time and correlation with vascular events (cerebral infarction, myocardial infarction, or vascular death)surrogate
Fluctuations in urinary 11-DTB2 after cerebral infarction in Black patients do not correlate with changes in aspirin doses or vascular events, except possibly with large dose reductions.
Limitations
- small sample size
Cite This Study
Bruno et al. (2004) studied this question.